Immunotherapy for prostatic cancer. Previous and prospective considerations.
D000818:Animals; D000912:Antibodies, Neoplasm; D000917:Antibody Formation; D001500:BCG Vaccine / Q000627:therapeutic use; D002454:Cell Differentiation; D003452:Cryosurgery; D005615:Freezing; D006801:Humans; D007109:Immunity; D007111:Immunity, Cellular; D007114:Immunization / Q000379:methods; D007116:Immunization, Passive; D007167:Immunotherapy; D008214:Lymphocytes / Q000276:immunology; D008297:Male; D010100:Oxygen / Q000097:blood; D010950:Plasma Cells / Q000276:immunology / Q000502:physiology; D010956:Plasmapheresis; D011471:Prostatic Neoplasms / Q000276:immunology / Q000517:prevention & control / Q000628:therapy*; D014374:Tuberculin Test
D000912:Antibodies, Neoplasm; D001500:BCG Vaccine; D010100:Oxygen